Fig. 4: POU4F1 activated MEK/ERK pathway to retain the resistance towards Vemurafenib in melanoma. | Cell Death & Disease

Fig. 4: POU4F1 activated MEK/ERK pathway to retain the resistance towards Vemurafenib in melanoma.

From: POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation

Fig. 4

a The expressions of MEK, p-MEK, ERK and p-ERK were analyzed by immunoblotting in parental and resistant melanoma cells with indicated treatments. b The mRNA expression level of MEK was detected by qRT-PCR in parental and resistant melanoma cells with POU4F1 knockdown or overexpression, n = 3. c, d The expressions of MEK, p-MEK, ERK and p-ERK were analyzed by immunoblotting in parental and resistant melanoma cells under the treatment of MEK inhibitor (PD98059). e Cell viability of resistant cells was measured by CCK8 assay with indicated treatment. n = 3. f Cell colony formation of resistant cells was measured by colony formation assay with indicated treatment, n = 3. Data are presented as the mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001. NC negative control. sh short hairpin RNA. OE over expressing. P parental cells. VR Vemurafenib-resistant cells. Vem Vemurafenib.

Back to article page